142 related articles for article (PubMed ID: 36050815)
1. Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set.
Tay J; ; Mårtensson B; Markus HS; Lundström E
Int J Stroke; 2023 Mar; 18(3):285-295. PubMed ID: 36050815
[TBL] [Abstract][Full Text] [Related]
2. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
[TBL] [Abstract][Full Text] [Related]
3. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
4. Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial.
Almeida OP; Hankey GJ; Ford A; Etherton-Beer C; Flicker L; Hackett M;
JAMA Neurol; 2021 Sep; 78(9):1072-1079. PubMed ID: 34338714
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.
EFFECTS Trial Collaboration
Lancet Neurol; 2020 Aug; 19(8):661-669. PubMed ID: 32702335
[TBL] [Abstract][Full Text] [Related]
6. Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial.
Lundström E; Isaksson E; Greilert Norin N; Näsman P; Wester P; Mårtensson B; Norrving B; Wallén H; Borg J; Hankey GJ; Hackett ML; Mead GE; Dennis MS; Sunnerhagen KS
Stroke; 2021 Oct; 52(10):3082-3087. PubMed ID: 34465201
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study.
Wiart L; Petit H; Joseph PA; Mazaux JM; Barat M
Stroke; 2000 Aug; 31(8):1829-32. PubMed ID: 10926942
[TBL] [Abstract][Full Text] [Related]
8. Depressive Symptoms in Stroke Patients: Are There Sex Differences?
Lee EJ; Kim JS; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S
Cerebrovasc Dis; 2020; 49(1):19-25. PubMed ID: 32023608
[TBL] [Abstract][Full Text] [Related]
9. Early apathetic, but not depressive, symptoms are associated with poor outcome after stroke.
Lopatkiewicz AM; Pera J; Slowik A; Dziedzic T
Eur J Neurol; 2021 Jun; 28(6):1949-1957. PubMed ID: 33619849
[TBL] [Abstract][Full Text] [Related]
10. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.
Robinson RG; Schultz SK; Castillo C; Kopel T; Kosier JT; Newman RM; Curdue K; Petracca G; Starkstein SE
Am J Psychiatry; 2000 Mar; 157(3):351-9. PubMed ID: 10698809
[TBL] [Abstract][Full Text] [Related]
11. Post-Stroke Depressive Symptoms: Varying Responses to Escitalopram by Individual Symptoms and Lesion Location.
Lee EJ; Kim JS; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S; Kim MS; Lee JS
J Geriatr Psychiatry Neurol; 2021 Nov; 34(6):565-573. PubMed ID: 32912058
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial.
AFFINITY Trial Collaboration
Lancet Neurol; 2020 Aug; 19(8):651-660. PubMed ID: 32702334
[TBL] [Abstract][Full Text] [Related]
13. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM
JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307
[TBL] [Abstract][Full Text] [Related]
15. Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.
Hankey GJ; Hackett ML; Almeida OP; Flicker L; Mead GE; Dennis MS; Etherton-Beer C; Ford AH; Billot L; Jan S; Lung T; Lundström E; Sunnerhagen KS; Anderson CS; Thang-Nguyen H; Gommans J; Yi Q;
Stroke; 2021 Aug; 52(8):2502-2509. PubMed ID: 34015940
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study.
Kim JS; Lee EJ; Chang DI; Park JH; Ahn SH; Cha JK; Heo JH; Sohn SI; Lee BC; Kim DE; Kim HY; Kim S; Kwon DY; Kim J; Seo WK; Lee J; Park SW; Koh SH; Kim JY; Choi-Kwon S;
Lancet Psychiatry; 2017 Jan; 4(1):33-41. PubMed ID: 28012485
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
Barbosa L; Berk M; Vorster M
J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
